Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
RT234 inhaled vardenafil dose-escalation study in pulmonary arterial hypertension
ACTRN12619001178134Phase 2Terminated
- Sponsor
- Respira Therapeutics
- Start
- Jul 2019
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label trial of vardenafil inhalation powder and vardenafil in pulmonary arterial hypertension (PAH) (3 cohorts), sponsored by Respira Therapeutics. Primary endpoints: Adverse events, Pharmacokinetic measures and 1 more. Started Jul 2019; status: terminated.
02
Drugs
vardenafil inhalation powdervardenafil
03
Conditions
pulmonary arterial hypertension (PAH)
Beyond the preview
Go deeper on ACTRN12619001178134.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ACTRN12619001178134.